Search the Newsreel

Lucara Diamond Q2 Results: EPS beats estimate, sales drop 6%

Lucara Diamond Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Bicara Therapeutics Inc (BCAX) Stock News Today

Bicara Therapeutics (BCAX.US) will release its earnings report before market open on August 11.

Bicara Therapeutics (BCAX.US) is scheduled to release its earnings report on August 11, before the market opens. This announcement informs investors and the public about the upcoming financial disclosure.

Carasso Real Estate Ltd. Revenue Breakdown – TASE:CRSR

Bicara Therapeutics Q2 Results: Financial update scheduled for August 11, 2026

Bicara Therapeutics Inc. will release its Q2 2026 financial results on August 11, 2026, before market open, followed by a conference call at 8:30 a.m. ET. The company, a clinical-stage biopharmaceutical firm, is focused on developing bifunctional therapies for solid tumors, with its lead …

Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday

Bicara Therapeutics will detail second-quarter results Aug. 11

Bicara Therapeutics (NASDAQ: BCAX) announced it will report its second quarter 2026 financial results and provide business updates before the market opens on Tuesday, August 11, 2026. The company will host a conference call at 8:30 a.m. ET the same day to discuss these …

Bicara Therapeutics to Report Second Quarter 2026 Financial

Bicara Therapeutics Inc. announced it will report its second quarter 2026 financial results and business updates on Tuesday, August 11, 2026, before the market opens. The company will host a conference call at 8:30 a.m. ET on the same day to discuss these updates. …

Janus Henderson Group PLC Acquires 692,933 Shares of Bicara Therapeutics Inc. $BCAX

Rock Springs Capital Management LP Raises Stock Holdings in Bicara Therapeutics Inc. $BCAX

Rock Springs Capital Management LP increased its stake in Bicara Therapeutics Inc. by 14% in the first quarter, now holding 489,095 shares valued at $9.7 million. Despite the company missing its Q1 earnings estimates with a loss of $0.93 per share, Bicara's stock opened …

Will New Oncology Veterans on Bicara Therapeutics' (BCAX) Board Reshape Its Late-Stage Strategy?

Bicara Therapeutics (BCAX) has appointed Jeremy Bender and Christy Oliger to its Board of Directors, bringing extensive oncology drug development and commercialization experience. These appointments could significantly influence the company's late-stage strategy for its lead asset, FICERA, particularly concerning its FORTIFI HN01 trial and …

Bicara Therapeutics (BCAX) director reports initial Form 3 filing

Bicara Therapeutics Inc. director Christy J. Oliger has filed an initial Form 3, an Initial Statement of Beneficial Ownership. The filing indicates no current equity or derivative security holdings and no reported transactions, with a reference to a Power of Attorney document. This report …

Bicara Therapeutics grants options to director | BCAX Insider Trading

Bicara Therapeutics (BCAX) has granted its director, Jeremy Bender, 38,950 stock options. These options have an exercise price of $26.88 per share and expire on July 28, 2036. The shares will vest in stages, with one-third vesting on July 28, 2027, and the remainder …

Bicara Therapeutics (BCAX) awards 38,950 stock options to board director

Bicara Therapeutics (BCAX) director Christy J. Oliger was granted 38,950 stock options with an exercise price of $26.88 per share, expiring on July 28, 2036. The options will vest one-third on July 28, 2027, with the remainder vesting in 24 equal monthly installments, contingent …

Bicara Therapeutics Inc. (BCAX) director Jeremy Bender files ownership report

Bicara Therapeutics Inc. director Jeremy Bender has filed an initial statement of beneficial ownership (Form 3), indicating his role as a director. The filing reports no transactions or specific equity holdings for Bender and refers to an accompanying Exhibit 24 - Power of Attorney. …

Caravel Minerals Limited Revenue Breakdown – ASX:CVV

Bicara Therapeutics Oliger Recently Served as Senior Vice Pres of the Oncology Business Unit at Genentech >BCAX

Bicara Therapeutics has appointed Natalie R. Oliger, an executive with significant oncology experience from Genentech, to its Board of Directors. Her appointment is expected to provide valuable strategic insights as Bicara advances its pipeline.

Bicara Therapeutics adds two directors to board

Bicara Therapeutics Inc. (NASDAQ:BCAX) has announced the appointment of Jeremy Bender and Christy Oliger to its board of directors, expanding its leadership team. Jeremy Bender brings over 20 years of experience in biotechnology, including leading Day One Biopharmaceuticals through its acquisition. Christy Oliger adds …

Bicara Therapeutics Announces Appointments Of Jeremy Bender And Christy Oliger To Board Of Directors

Bicara Therapeutics has announced the appointments of Jeremy Bender and Christy Oliger to its Board of Directors. This news was reported by Refinitiv and is available on TradingView. The article indicates that full access to the content is available on TradingView, along with other …

HTCO|High-Trend International Group|Price:3.250|Chg%:-0.150

High-Trend International Group (HTCO), formerly Caravelle International Group, is an ocean technology company specializing in international shipping services and a carbon-neutral wood desiccation solution called CO-Tech. The company's business is divided into traditional international shipping and the innovative CO-Tech sector, which utilizes waste heat …

Bicara Therapeutics Inc (BCAX) Earnings Date & Reports & Earnings News

Carasso Motors Ltd Revenue Breakdown – TASE:CRSM

BlackRock (BCAX holder) discloses 5.4% Bicara Therapeutics stake on Schedule 13G

BlackRock, Inc. has filed a Schedule 13G, disclosing a passive ownership stake of 5.4% in Bicara Therapeutics Inc. (BCAX). As of June 30, 2026, BlackRock beneficially owned 3,536,271 shares of Bicara's common stock, holding sole voting power over 3,464,981 shares and sole dispositive power …

Bicara Therapeutics Inc (BCAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Bicara Therapeutics Inc (BCAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Bicara Therapeutics Inc (BCAX), detailing its performance based on various indicators and moving averages. It offers insights into the stock's current technical status, including buy/sell signals from MACD, RSI, and different moving averages. The analysis concludes with …

Bicara Therapeutics Inc (BCAX) Cash Flow

This article provides a detailed cash flow statement for Bicara Therapeutics Inc (BCAX), including operating, investing, and financing cash flows presented quarterly and annually. It also includes an FAQ section explaining key cash flow concepts and specific figures for BCAX, such as operating cash …

BCAX|Bicara Therapeutics Inc|Price:27.020|Chg%:-0.710

This article provides a detailed financial overview of Bicara Therapeutics Inc (BCAX), including its current stock price, market capitalization, key financial figures, and recent performance. It also includes analyst ratings, indicators, and company information, emphasizing its focus on developing bifunctional therapies for solid tumors. …

Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Moderate Buy" by Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received an average "Moderate Buy" rating from fifteen analysts, with a consensus 12-month price target of $30.27. Despite the stock trading near its 1-year high, the company reported an EPS loss that missed estimates, and internal insider selling has …

Lucara Diamond Corp. Revenue Breakdown – TSX:LUC

Caravel Minerals (ASX: CVV) Drops — Is Investor Support for the Copper Story Weakening?

High-Trend International Group Posts Strong Revenue Growth but Ongoing Losses in First Half 2026

High-Trend International Group (HTCO) reported strong revenue growth in the first half of 2026, with ocean freight revenue rising to $136.9 million and total revenue reaching $137.5 million, up from $99.4 million a year prior. Despite this growth and stable gross profit, the company …

Bicara Therapeutics (BCAX) Proxy filing Summary

Bicara Therapeutics (BCAX) will hold its annual meeting virtually on June 9, 2026, where shareholders will vote on the election of two Class II directors and the ratification of KPMG LLP as the independent auditor for 2026. The board recommends voting in favor of …

Bicara Therapeutics (BCAX) Corporate presentation Summary

Bicara Therapeutics (BCAX) presented a corporate summary focusing on its lead candidate, ficerafusp alfa (FICERA), a bifunctional antibody targeting EGFR and TGF-β for HPV-negative head and neck squamous cell carcinoma (HNSCC). The company highlighted FICERA's potential for blockbuster status, given its strong clinical efficacy—demonstrating …

Bicara Therapeutics (BCAX) Study update Summary

Bicara Therapeutics (BCAX) released a study update on May 22, 2026, detailing the efficacy and safety of Ficera (ficerafusp alfa) plus pembrolizumab in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC). The phase 1/1b expansion cohorts showed nearly double the three-year overall …

Bicara Therapeutics (BCAX) Q1 2026 earnings summary

Bicara Therapeutics (BCAX) reported its Q1 2026 earnings, highlighting progress in its pivotal FORTIFI-HN01 trial for ficerafusp alfa, with enrollment expected by year-end 2026 and interim analysis in mid-2027. The company's cash reserves increased to $539.8M following a $161.8M public offering, extending its cash …